🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for ER-Positive HER2-Negative Breast Cancer

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites📍 Duarte📍 Grand Rapids📍 Long Island City Pfizer · Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261Phase 23 sites📍 Miami📍 Boston📍 Durham Nancy Lin, MD · Tests: Datopotamab Deruxtecan A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer NCT04985266Phase 249 sites📍 Angers📍 Annecy📍 Avignon Royal Marsden NHS Foundation Trust · Tests: Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients NCT06195709Phase 321 sites📍 Bayonne📍 Bordeaux📍 Bordeaux Institut Curie · Tests: Endocrine therapy, Endocrine therapy combined with the local treatment of FES-negative lesions, Chemotherapy Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer NCT02535221Phase 31 site📍 Beijing Peking University · Tests: Goserelin+TAM+AI, Epirubicin+CTX+5-Fu A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer NCT07100106Phase 1, Phase 277 sites📍 Huntsville📍 Tucson📍 Duarte Genentech, Inc. · Tests: GDC-4198, Giredestrant, Abemaciclib Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor NCT05181033Phase 21 site📍 Singapore National University Hospital, Singapore · Tests: Lenvatinib + Letrozole, Fulvestrant A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC NCT07002177Phase 1, Phase 21 site📍 Shanghai Forward Pharmaceuticals Co., Ltd. · Tests: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG, Everolimus 10 mg Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites📍 Aviano📍 Brescia📍 Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Palbociclib, Ribociclib, Abemaciclib A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer NCT06062498Phase 23 sites📍 Chicago📍 Chicago📍 Chicago Northwestern University · Tests: elacestrant, palbociclib, abemaciclib, ribociclib Role of the Immune Environment in Response to Therapy in Breast Cancer NCT05396612n/a1 site📍 Philadelphia Abramson Cancer Center at Penn Medicine · Tests: Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA … OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk NCT05333328Phase 42 sites📍 Seoul📍 Seoul Gangnam Severance Hospital · Tests: Ovarian function suppression with endocrine treatments A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer NCT04872166Phase 16 sites📍 Lake Mary📍 Sarasota📍 Cincinnati Edgewood Oncology Inc. · Tests: BTX-A51 Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites📍 Phoenix📍 Irvine📍 San Diego RayzeBio, Inc. · Tests: RYZ101, Standard of Care Endocrine Therapy Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer NCT06167694Phase 1, Phase 22 sites📍 Beijing📍 Guangzhou Shandong Suncadia Medicine Co., Ltd. · Tests: HRS-8080; Dalpiciclib Isethionate Tablets NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline NCT06452394Phase 28 sites📍 Sankt Gallen📍 Genolier📍 Winterthur Swiss Cancer Institute · Tests: Doxycyclin Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial NCT07391774Phase 3226 sites📍 Jonesboro📍 Auburn📍 Berkeley National Cancer Institute (NCI) · Tests: Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography Breast Re-irradiation After Second Ipsilateral Lumpectomy NCT06867484NA2 sites📍 Boca Raton📍 Miami Youssef Zeidan · Tests: Intensity modulated radiation therapy (IMRT) Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy NCT06953882Phase 21 site📍 New Haven Yale University · Tests: Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 NCT05879926Phase 31261 sites📍 Birmingham📍 Anchorage📍 Anchorage NRG Oncology · Tests: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression Capecitabine in ER+/HER2-negative Breast Cancer NCT07631052Phase 21 site📍 Toronto University Health Network, Toronto · Tests: Capecitabine To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer NCT04660435n/a1 site📍 Prato Fondazione Sandro Pitigliani · Tests: Thymidine kinase activity A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence NCT06492616Phase 3567 sites📍 Daphne📍 Chandler📍 Gilbert Stemline Therapeutics, Inc. · Tests: Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer NCT07647328Phase 389 sites📍 Duarte📍 Palo Alto📍 Marietta AstraZeneca · Tests: Camizestrant, Ribociclib Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites📍 Jonesboro📍 Little Rock📍 Duarte Celcuity Inc · Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Let… A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) NCT07541079Phase 38 sites📍 Fountain Valley📍 Stockton📍 Washington D.C. Genentech, Inc. · Tests: Giredestrant S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer NCT03723928NA723 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Ques… Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy NCT02945579NA8 sites📍 Gilbert📍 Jacksonville📍 Honolulu M.D. Anderson Cancer Center · Tests: Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast I… Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib NCT06341621Phase 31 site📍 Shanghai Fudan University · Tests: 3-year abemaciclib without chemo, treatment of physician's choice
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy